Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Nurix Therapeutics Inc (NASDAQ: NRIX) was $13.59 for the day, down -5.89% from the previous closing price of $14.44. In other words, the price has decreased by -$5.89 from its previous closing price. On the day, 1.02 million shares were traded. NRIX stock price reached its highest trading level at $14.84 during the session, while it also had its lowest trading level at $12.945.
Ratios:
Our analysis of NRIX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.13.
On March 09, 2023, Barclays started tracking the stock assigning a Overweight rating and target price of $20.
On February 28, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $25.Oppenheimer initiated its Outperform rating on February 28, 2023, with a $25 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 16 ’24 when van Houte Hans sold 6,812 shares for $10.02 per share. The transaction valued at 68,223 led to the insider holds 68,333 shares of the business.
Hansen Gwenn sold 2,334 shares of NRIX for $18,649 on Jan 30 ’24. The Chief Scientific Officer now owns 36,402 shares after completing the transaction at $7.99 per share. On Jan 30 ’24, another insider, Ring Christine, who serves as the Chief Legal Officer of the company, sold 1,760 shares for $7.99 each. As a result, the insider received 14,063 and left with 17,427 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRIX now has a Market Capitalization of 829907328 and an Enterprise Value of 453122304. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.97 while its Price-to-Book (P/B) ratio in mrq is 3.96. Its current Enterprise Value per Revenue stands at 5.602 whereas that against EBITDA is -3.003.
Stock Price History:
Over the past 52 weeks, NRIX has reached a high of $18.12, while it has fallen to a 52-week low of $4.22. The 50-Day Moving Average of the stock is 4.71%, while the 200-Day Moving Average is calculated to be 45.78%.
Shares Statistics:
NRIX traded an average of 990.89K shares per day over the past three months and 1931200 shares per day over the past ten days. A total of 59.32M shares are outstanding, with a floating share count of 54.63M. Insiders hold about 7.90% of the company’s shares, while institutions hold 69.87% stake in the company. Shares short for NRIX as of 1711584000 were 6969094 with a Short Ratio of 7.03, compared to 1709164800 on 6846388. Therefore, it implies a Short% of Shares Outstanding of 6969094 and a Short% of Float of 15.720001.
Earnings Estimates
The dynamic stock of Nurix Therapeutics Inc (NRIX) is currently attracting attention from Neurocrine Biosciences, Inc. analysts actively involved in rating its market status.The consensus estimate for the next quarter is $13.59, with high estimates of $2.87 and low estimates of $46.39.
